Trial site
Hospital Universitario Clínico San Carlos
Madrid, Madrid 28040, SpainNot linked to an institution yet
- 11running trials
- 15closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 23 trials
- Phase 2/32 trials
- Status
- Completed13 trials
- Active, not recruiting5 trials
- Recruiting4 trials
- Not yet recruiting2 trials
- Terminated2 trials
- Lead sponsor
- Hoffmann-La Roche6 trials
- Daiichi Sankyo2 trials
- Aarhus University Hospital Skejby1 trial
- Ab Science1 trial
- ARCAGY/ GINECO GROUP1 trial
- and 15 more
Running trials
Recruiting
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
NCT07583446· Phase 2/3· Seismic Pharmaceuticals Operations LLC· Source
Not yet recruiting
Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population
NCT07394556· Indizen Optical Technologies, S.L.U.· Source
Contact: Noemi Güemes Villahoz
Recruiting
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
NCT07465848· Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)· Source
Contact: Mónica Antoñanzas, MD
Recruiting
Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
NCT07255378· Jamil Cedeño Mora· Source
Contact: Fernando Martínez-Sagasti
Active, not recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source
Recruiting
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05558319· Phase 3· PETHEMA Foundation· Source
Contact: Celina María Benavente Cuesta
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092· Phase 3· Hoffmann-La Roche· Source
Recruiting
ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO
NCT03563417· Aarhus University Hospital Skejby· Source
Contact: Javier Escaned, MD
Active, not recruiting
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· Phase 3· Eisai Inc.· Source
Active, not recruiting
BAsel Syncope EvaLuation (BASEL IX) Study
NCT01548352· University Hospital, Basel, Switzerland· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
NCT05847517· Phase 3· Consorcio Centro de Investigación Biomédica en Red (CIBER)· Source
Completed
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
2024-516672-16-00· Phase 3· Ab Science· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501· Phase 2· Hoffmann-La Roche· Source
Completed
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
NCT04603183· Phase 2· MedSIR· Source
Completed
Multicentric Clinical Study on Isatis TF Trifocal Intraocular Lens
NCT04465344· Cutting Edge SAS· Source
Completed
SAPIEN 3 Ultra EU PMS
NCT04860752· Edwards Lifesciences· Source
Completed
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia
NCT04864795· Vifor (International) Inc.· Source
Completed
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
NCT04986085· Grupo Espanol de Tumores Neuroendocrinos· Source
Terminated
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
NCT04449588· Phase 2/3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Completed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· Phase 3· Daiichi Sankyo· Source
Completed
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03523585· Phase 3· Daiichi Sankyo· Source
Completed
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT03599245· Phase 3· Hoffmann-La Roche· Source
Completed
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source
Completed
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636· Phase 3· Hoffmann-La Roche· Source
Completed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267· Phase 2· Hoffmann-La Roche· Source
Report an error